CBD Life Sciences Inc. (CBDL) in Final Stages to Sell CBD Products on DoorDash Platform
CBD Life Sciences Inc. (CBDL) announces it's in final stages of approval to sell CBD products on DoorDash, projected to generate $10 billion in revenue by 2025. This strategic move is expected to drive a 30-40% increase in CBDL's annual revenue. The company plans to offer bestselling products including 3000MG Pain Relief Cream and CBD Gummies with same-day delivery in select markets.
The partnership leverages DoorDash's extensive logistics network to enhance CBDL's market reach and product accessibility. The U.S. CBD market is projected to grow at a 28% CAGR over the next five years. CEO Lisa Nelson emphasizes this opportunity as a game-changer for market penetration and brand recognition. The company continues to focus on R&D efforts and exploring additional partnerships for both domestic and international market expansion.
CBD Life Sciences Inc. (CBDL) annuncia di essere nelle fasi finali di approvazione per vendere prodotti a base di CBD su DoorDash, con previsioni di generare $10 miliardi di entrate entro il 2025. Questa mossa strategica è destinata a guidare un aumento del 30-40% delle entrate annuali di CBDL. L'azienda prevede di offrire prodotti best-seller tra cui la Crema Antidolorifica da 3000MG e le Gummy al CBD con consegna lo stesso giorno in mercati selezionati.
La partnership sfrutta l'ampia rete logistica di DoorDash per migliorare la portata sul mercato di CBDL e l'accessibilità dei prodotti. Si prevede che il mercato del CBD negli Stati Uniti crescerà con un CAGR del 28% nei prossimi cinque anni. L'Amministratore Delegato Lisa Nelson enfatizza questa opportunità come un punto di svolta per la penetrazione del mercato e il riconoscimento del marchio. L'azienda continua a concentrarsi sugli sforzi di ricerca e sviluppo ed esplorare ulteriori partnership sia per l'espansione del mercato domestico che internazionale.
CBD Life Sciences Inc. (CBDL) anuncia que se encuentra en las etapas finales de aprobación para vender productos de CBD en DoorDash, con proyecciones de generar $10 mil millones en ingresos para 2025. Este movimiento estratégico se espera que impulse un aumento del 30-40% en los ingresos anuales de CBDL. La empresa planea ofrecer productos más vendidos que incluyen Crema Alivio del Dolor de 3000MG y Gominolas de CBD con entrega el mismo día en mercados seleccionados.
La asociación aprovecha la extensa red logística de DoorDash para mejorar el alcance del mercado de CBDL y la accesibilidad de los productos. Se proyecta que el mercado de CBD en EE. UU. crecerá a un CAGR del 28% en los próximos cinco años. La CEO Lisa Nelson enfatiza esta oportunidad como un cambio de juego para la penetración del mercado y el reconocimiento de la marca. La empresa continúa enfocándose en los esfuerzos de I+D y explorando asociaciones adicionales tanto para la expansión del mercado doméstico como internacional.
CBD 라이프 사이언스 주식회사 (CBDL)은 DoorDash에서 CBD 제품 판매 승인의 최종 단계에 있으며, 2025년까지 100억 달러의 수익을 창출할 것으로 예상하고 있습니다. 이 전략적 움직임은 CBDL의 연간 수익 증가를 30-40% 이끌 것으로 기대됩니다. 회사는 3000MG 통증 완화 크림과 CBD 구미와 같은 베스트셀러 제품을 제공하며, 특정 시장에서 당일 배송을 계획하고 있습니다.
이 파트너십은 DoorDash의 방대한 물류 네트워크를 활용하여 CBDL의 시장 도달 범위와 제품 접근성을 개선합니다. 미국의 CBD 시장은 향후 5년 동안 28% CAGR로 성장할 것으로 예상됩니다. CEO 리사 넬슨은 이 기회를 시장 침투와 브랜드 인지도를 위한 게임 체인저로 강조합니다. 회사는 R&D 노력을 계속하고 국내 및 국제 시장 확장을 위한 추가 파트너십을 탐색하고 있습니다.
CBD Life Sciences Inc. (CBDL) annonce qu'elle est dans les dernières étapes de validation pour vendre des produits CBD sur DoorDash, avec une prévision de générer 10 milliards de dollars de chiffre d'affaires d'ici 2025. Ce mouvement stratégique devrait entraîner une augmentation de 30 à 40 % du chiffre d'affaires annuel de CBDL. La société prévoit d'offrir des produits best-sellers tels que la Crème Analgésique 3000MG et des Gummies au CBD avec livraison le jour même dans certains marchés.
Le partenariat tire parti du vaste réseau logistique de DoorDash pour améliorer la portée et l'accessibilité des produits de CBDL. Le marché du CBD aux États-Unis devrait croître à un CAGR de 28% au cours des cinq prochaines années. La PDG Lisa Nelson souligne cette opportunité comme un véritable tournant pour la pénétration du marché et la reconnaissance de la marque. L'entreprise continue de se concentrer sur les efforts de R&D et d'explorer des partenariats supplémentaires tant pour l'expansion du marché national qu'international.
CBD Life Sciences Inc. (CBDL) gibt bekannt, dass sich das Unternehmen in den letzten Zügen der Genehmigung zur Verkaufs von CBD-Produkten über DoorDash befindet, wobei bis 2025 ein Umsatz von 10 Milliarden Dollar prognostiziert wird. Diese strategische Entscheidung wird voraussichtlich zu einer Steigerung des Jahresumsatzes von CBDL um 30-40% führen. Das Unternehmen plant, Bestseller-Produkte wie die 3000MG Schmerzcreme und CBD-Gummis mit Lieferung am selben Tag in ausgewählten Märkten anzubieten.
Die Partnerschaft nutzt das umfangreiche Logistiknetz von DoorDash, um die Marktpräsenz und Produktverfügbarkeit von CBDL zu verbessern. Der US-CBD-Markt wird voraussichtlich in den nächsten fünf Jahren mit einem CAGR von 28% wachsen. CEO Lisa Nelson hebt diese Gelegenheit als einen Wendepunkt für die Marktdurchdringung und Markenbekanntheit hervor. Das Unternehmen konzentriert sich weiterhin auf F&E-Maßnahmen und erkundet zusätzliche Partnerschaften sowohl für die nationale als auch für die internationale Markterweiterung.
- Projected 30-40% increase in annual revenue through DoorDash partnership
- Access to DoorDash's extensive delivery network and customer base
- Same-day delivery capability in select markets
- Operating in CBD market with 28% projected CAGR over next 5 years
- Partnership still pending final approval
- to select markets for same-day delivery
- Success dependent on DoorDash platform performance
With DoorDash projecting over
SCOTTSDALE, ARIZONA / ACCESSWIRE / January 14, 2025 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD industry, proudly announces that it is in the final stages of securing approval to sell its premium CBD products on DoorDash, one of the most prominent on-demand delivery platforms in the United States. This development represents a significant step forward in CBDL's ongoing strategy to broaden its market reach and deliver high-quality CBD offerings to customers with greater convenience.
DoorDash's projected multi-billion-dollar revenue for 2025 underscores the massive growth potential in on-demand services. With a footprint spanning millions of households across the nation, DoorDash provides a unique and scalable avenue for CBDL to reach an even broader audience, enhancing product accessibility and driving exponential revenue growth. The CBD industry continues to surge, and this opportunity positions CBDL as a key player in transforming how consumers access wellness products.
"Being able to sell on DoorDash opens up an entirely new market for us," said Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are excited about the prospect of making our premium CBD products available through one of the most trusted delivery platforms in the U.S. This move not only aligns with our commitment to innovation but also positions us for substantial revenue growth in 2025 and beyond."
Once approved, CBDL plans to offer a wide range of its bestselling products, including high-potency 3000MG Pain Relief Cream and CBD Gummies, with same-day delivery in select markets. The company's CBD Gummies, known for their consistency and great taste, have been a hit with customers seeking convenient, delicious ways to incorporate wellness into their daily lives. This initiative enhances CBDL's competitive edge by catering to consumer demand for fast, convenient access to wellness products.
Expanding Market Potential and Growing Investor Confidence
In addition to expanding distribution channels, this opportunity also reinforces CBDL's aggressive growth strategy aimed at increasing shareholder value. Recent industry reports indicate that the U.S. CBD market is poised to grow at a compound annual growth rate (CAGR) of
CBDL's focus on innovation doesn't stop at delivery partnerships. The company is also ramping up research and development efforts to introduce new products that cater to evolving consumer needs. These efforts reflect CBDL's dedication to staying ahead of market trends and ensuring sustained growth.
"This DoorDash opportunity is a game-changer," Nelson added. "It positions us at the forefront of a rapidly evolving market and gives us a significant advantage in capturing more market share while providing a seamless buying experience for our customers. We anticipate strong revenue growth and improved brand recognition as a direct result of this initiative."
CBDL continues to explore additional partnerships and opportunities to expand its reach in both the U.S. and international markets. With a strong product portfolio, a robust distribution strategy, and a relentless focus on growth, the company remains dedicated to delivering long-term value to its investors. Additionally, the company is committed to ongoing product innovation to meet the evolving needs of health-conscious consumers.
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC: CBDL) is a vertically integrated company focused on the development and commercialization of high-quality, innovative CBD-based products. With a diverse product line ranging from pain relief creams to gummies, CBDL is committed to enhancing the well-being of its customers through science-backed solutions. The company's mission is to lead the CBD industry by delivering exceptional products that promote better living.
For more information about CBD Life Sciences, Inc. and its product offerings, visit www.thecbdvault.com
Doordash Website: https://www.doordash.com/
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What revenue increase does CBDL expect from the DoorDash partnership?
Which CBDL products will be available on DoorDash?
What is the projected CAGR for the U.S. CBD market according to CBDL's announcement?
When will CBDL products be available on DoorDash?
Will CBDL offer same-day delivery through DoorDash?
